Injection Pen Market Research Report: By Type (Disposable Injection Pens, Others), by Product (Insulin Pens, Pen Needles), by Therapy (Diabetes, Others), by Distribution Channel (Hospital Pharmacies, Others), by End-User – Global Forecast Till 2030

Injection Pen Market Overview

The worldwide injection pen market is predicted to grow at a CAGR of 6.9% with value of USD 73.3 billion during the forecast timeframe (2022-2030). Injection pens are intended to deliver drugs into the system with as little difficulty and as little inconvenience as possible. It is a compact, transportable gadget that may be carried in one's hand and then used to administer drugs for the therapy of numerous ailments. It is anticipated that the rising prevalence of chronic disorders like osteoporosis and diabetes would propel the worldwide injection pen market value during the projected period. For example, as per the American Diabetes Association, about 30.3 million persons in the United States were diagnosed with diabetes in the year 2015, accounting for 9.4 percent of the total population. A further factor contributing to market expansion is the increased preference for injectable pens over the conventional vial and needle approach, which is being driven by an increase in the number of incidences of needle stick injury.

This report contains all the information on the global injection pen market analysis and its strengths. The report also contains the culmination of dynamics, segmentation, key players, regional analysis, and other important factors.

Covid 19 Analysis

According to market research, the COVID-19 outbreak had no substantial influence, mostly on the injection pen business. Individuals who were previously utilizing injectable pens for a variety of treatments remained to do so throughout the epidemic. In contrast, the distribution system for injection pens has been affected as a result of movement limitations, border closures, and a general reduction in global commerce. Patients who have been infected with COVID-19 and have undergone therapy are at an increased risk of developing diabetes. As a result, the prevalence of diabetes continues to rise, increasing the need for insulin injection pens.

Injection Pen Market Dynamic

• Drivers

Chronic illnesses have become more common in recent years. Diabetes, cardiovascular disease, osteoporosis, and multiple sclerosis all need daily or weekly injections. Chronic conditions need frequent medication delivery, making injector pens ideal. Injectable medication delivery methods now include injection pens. They have gained in demand because of their ease of use and capability to be self-administered without a specialist. As chronic illnesses become more common, the need for injectable pen technologies has increased to properly address the rising patient pool and promote treatment adherence. 

• Opportunities

Considering that many implants for chronic illnesses are biologics, the expiration of copyrights and increasing funding agencies and insurance companies present an opportunity for expansion of the injection pen market growth.

Restraints

While there are a number of reasons driving the worldwide injection pen market, reasons such as financing challenges in developing nations and a preference for other forms of medication administration are limiting its expansion.

• Challenges

The absence of sufficient training and instruction for using novel delivery methods, such as injectable pens, results in their wrong usage, which may endanger the security of both personnel and clients in the facility. In a hospital context, such procedures may have an impact on the use of injectable pens.

Cumulative Growth Analysis

Due to the obviously large number of patients suffering from chronic illnesses in the Asia Pacific, the area is the quickest expanding in the market. As per the World Health Organization, Asia Pacific is home to 60 percent of the nation's diabetes population. This is one of the most important factors contributing to the industry's rapid expansion in this area. Additional research from the Asian Pacific Journal of Tropical Biomedicine Journal, released in 2014, projected that the area is home to over 150 million diabetic people, with more than 95 percent of those suffering from type 2 diabetes mellitus. Moreover, the quick progress of economies, as well as the rise in healthcare spending, has propelled the expansion of the industry.

Value Chain Analysis

According to the reports, the worldwide injection pen market is split on the basis of type, product, treatment, distribution channel, end-user, and regions. The market may be divided into two categories based on the kind of injection pen used: disposable injection pens and reusable injection pens. The worldwide injection pen market's insulin pens and pen needles segments are further subdivided based on the product. Diabetes, growth hormone treatment, cardiovascular disorders, fertility, rheumatoid arthritis, osteoporosis, multiple sclerosis, obesity, Crohn's disease, malignancy, and other ailments are among the therapeutic areas covered by the market, which is further subdivided. Diabetes is further subdivided into two types: insulin-dependent and GLP-1-dependent.

The market is categorized based on the distribution channel used, with retail pharmacies, hospital pharmacies, online medical shops, and diabetic clinics being the most common. The worldwide injection pen market is classified into two types of end-users: home care and clinics and hospitals. Home care is the largest category, followed by hospitals and clinics.

Segmentation Overview

The market is segmented on the basis of the type, product, treatment, distribution channel, end-user, and regions. The global injection pen market trends are expected to witness decent growth during the forecast period.

By Application

Based on the Application, the market is segmented into diabetes, growth hormone treatment, cardiovascular disorders, fertility, rheumatoid arthritis, osteoporosis, multiple sclerosis, obesity, Crohn's disease, malignancy, and other ailments.

By end-users

Based on the propulsion types, the market is segmented into retail pharmacies, hospital pharmacies, online medical shops, and diabetic clinics.

Regional Analysis

From a regional standpoint, the market has just been split into the following regions: North America, Europe, Asia Pacific, the Middle East, and Africa. Yet another division of the North American injection pen market may be found in South America and North America. North America is further subdivided into the United States and Canada. It is expected that the Americas would lead the worldwide injection pen market share during the projection timeframe due to the rising rates of diabetes and tumors, an uptick in the frequency of drugs approved, and the launch of new technology in the region. 

For example, according to the National Diabetes Statistics Report of 2014, near about 29.1 million individuals, or 9.3 percent of the inhabitants of the United States, were diagnosed with diabetes. The continual innovation of improved injection pens by producers in the area also helps to the expansion of the injection pen market outlook.

Competitive landscape

Those involved with the injection pen industry have set their sights on broadening their geographical scope via agreements with companies all around the globe. A rising number of businesses are turning to acquisitions and mergers for their most important strategic decisions in order to develop and improve their position around the globe. On the other hand, product releases have maintained one of the most important methods used by players.

Major Key Players

• Novo Nordisk


• Eli Lilly


• Sanofi


• Merck


• Ypsomed


• AstraZeneca


• Hoffman-La Roche


• Becton Dickinson and Company


• Owen Mumford


• Novartis


• Pfizer


• Haselmeier


• Jiangsu Delfu medical device Co., Ltd


• Biocon Ltd

Report Overview

The following report comprises of –

• Report Overview

The following report comprises of –

• Market overview


• Covid 19 Analysis


• Market Dynamic


• Drivers


• Opportunities


• Restraints


• Challenges


• Cumulative Growth Analysis


• Value Chain Analysis


• Segmentation Overview


• Regional Analysis


• Competitive landscape

Recent Developments

Sanofi (France) got FDA clearance for a new Dupixent prefilled pen in April 2020 for use in the treatment of chronic rhinosinusitis with nasal polyposis, asthma, and atopic dermatitis. The pen will be available for at-home administration.

Toujeo SoloStar Pens, manufactured by Sanofi (France), was approved in Europe in June of this year.

As of January 2019, Pergoveris, an injectable gonadotropin pen for reproductive therapy, was made available by Merck KGaG (Germany).

By Type

• Disposable injection pens


• Reusable injection pens

By Product

• Insulin Pens


• Pen Needles

By Therapy

• Diabetes


• Insulin


• GLP-1


• Growth hormone therapy


• Fertility


• Osteoporosis


• Multiple sclerosis


• Cardiovascular diseases


• Rheumatoid arthritis


• Obesity


• Crohn's disease


• Cancer


• Others

By Distribution Channel

• Hospital Pharmacies


• Retail Pharmacies


• Online Medical Stores


• Diabetes Clinics

By End-User

• Home care


• Hospital & Clinics

By Region

Americas

• North America 
  
  
  
  • The U.S.
  
  
  • Canada
  
  
  
  


• South America

Europe

• Western Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • Italy
  
  
  • Spain
  
  
  • The U.K.
  
  
  
  


• Rest of Western Europe


• Eastern Europe


• Asia Pacific
  
  
  
  • Japan
  
  
  • China
  
  
  • India
  
  
  • Australia
  
  
  • Republic of Korea
  
  
  • Rest of Asia Pacific
  
  
  
  


• The Middle East & Africa
  
  
  
  • Middle East
  
  
  • Africa